IGC Announces Fiscal 2024 Financial Results for Year Ended March 31


IGC Pharma, Inc. (NYSE American: IGC), a leading clinical-stage pharmaceutical company, recently reported its financial results for the fiscal year ended March 31, 2024 (Fiscal 2024). The company has made significant strides in advancing its pipeline of innovative therapies targeting various critical illnesses.

During Fiscal 2024, IGC Pharma achieved several key milestones, including the successful completion of Phase II clinical trials for its lead candidate, IGC-101, a novel treatment for glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. The company also initiated Phase I trials for IGC-201, a potential breakthrough therapy for Alzheimer’s disease.

IGC Pharma’s strong financial performance in Fiscal 2024 reflects the company’s dedication to research and development, as well as its commitment to bringing life-changing treatments to patients in need. With a robust pipeline and a solid financial foundation, IGC Pharma is well-positioned to continue its mission of developing groundbreaking therapies for complex diseases.